US-China GPCR Research Consortium Adds Two Pharma Members

The GPCR Consortium, a nonprofit US-China research collaboration, has added two new pharma members: Novo Nordisk and Merck. The academic members of the Consortium -- the Bridge Institute at the University of Southern California, the Shanghai Institute of Materia Medica, and the iHuman Institute at ShanghaiTech University -- remain the same. The Consortium's goal is to fully characterize the structure and function of 200 GPCRs, placing their findings in the public domain, with a goal of improving drug discovery. The companies underwrite the research performed at the academic institutes. More details..... Stock Symbols: (NYSE: NVO) (NYSE: MRK) Share this with colleagues: // //